Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
In summary, available data demonstrate that IL-1 and TNF are the causative agents underlying the bone loss induced by estrogen deficiency. Indeed, these factors are produced in bone and the bone marrow, released in larger amounts from cells of estrogen-deficient subjects, and indispensable for reproducing the effects of estrogen deficiency in bone. These observations support the hypothesis that the bone sparing effect of estrogen is due to the ability of the hormone to block osteoclastogenesis, the activation of mature osteoclasts and, as recently demonstrated, the rate of apoptotic osteoclast death. Although IL-1 and TNF play a prominent causal role in these events, the bone-sparing effect of estrogen is mediated by numerous cytokines which, by simultaneously stimulating multiple target cells, induce effects that are not accounted for by any one single factor (Fig. 2). The ability of estrogen to regulate some, but not all, the cytokines involved in this process is not inconsistent with this hypothesis because cytokines have potent synergistic effects. Thus, a considerable increase in bone resorption may result from a relatively small increase in the concentration of only a few of the bone-resorbing factors present in the bone microenvironment. This concept is best illustrated by the study of Miyaura et al. demonstrating that the concentrations of either IL-1, IL-6, IL-6 receptor, or prostaglandins detected in the bone marrow of OVX mice are insufficient to account for the increased bone resorption caused by estrogen withdrawal. In contrast, the increase in bone resorption induced by OVX can be explained by the cumulative effects of these cytokines. Thus, a better understanding of the cooperative effects of cytokines and a recognition that the contribution of individual cytokines to postmenopausal bone loss varies with the passage of time after menopause are necessary to fully understand the mechanism of action of estrogen in bone. Although the relevance of individual bone-targeting cytokines in species specific, the development of transgenic mice with activatable or deactivatable promoters is likely to result in a further clarification of the integrated action of estrogen-regulated cytokines in human bone cells and lay the foundations for the use of cytokine inhibitors in the treatment of postmenopausal osteoporosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estrogen acts via suppression of bone resorption [43–45]”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [44]
In the citing paper
“In addition, estrogen inhibits osteoclast formation by reducing the levels of other osteoclastogenic cytokines such as IL-1, IL-6, IL-11, TNF-α, TNF-β, and M-CSF [160, 161].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [160]
Citations
Cites
Interleukin-1 and interleukin-1 antagonism
Dinarello, C. (1991) · Blood · doi:10.1182/blood.v77.8.1627.1627 · Cited by 2,304
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B., Broxmeyer, H., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,442
Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D., & Mundy, G. R. (1986) · Nature · doi:10.1038/319516a0 · Cited by 1,434
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
An interleukin 1 like factor stimulates bone resorption in vitro
Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. B., & Russell, R. G. G. (1983) · Nature · doi:10.1038/306378a0 · Cited by 1,012
Modulation of Osteoclast Differentiation
SUDA, T., TAKAHASHI, N., & MARTIN, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004 · cited 2×
“(22) These mice, which are cured by the administration of M-CSF,(3s) have an extra thymidine inserted within the coding region of the M-CSF gene, a mutation that generates a stop codon within the coding sequence,(3h) thereby resulting in the production of a defective M-CSF.(22) The formation of osteoclasts in bone mar…”
BackgroundSoluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y., Ohsugi, Y., Kumaki, K., & Taga, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11924 · Cited by 825
TURNER, R. T., RIGGS, B. L., & SPELSBERG, T. C. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-275 · Cited by 754
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.
Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G., Rodan, G. A., & Costantini, F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06368.x · Cited by 749
Research works printed but not linked: 11
- Srivastava, 1995, Estrogen down-regulates the expression of M-CSF mRNA in bone marrow stromal cells by stimulating the production of the transcription factor EGR-1, J Bone Miner Res, 10, S18
- Matayoshi, 1995, Generation of human osteoclasts from peripheral blood cd 34+ cells, J Bone Miner Res, 10
- Pacifici, 1990, TNFα and GM-CSF secretion from human blood monocytes: Effect of menopause and estrogen replacement, J Bone Miner Res, 5, 145
- Kimble, 1996, Estrogen inhibits IL-1 and TNF gene expression in transfected murine macrophagic cells, J Bone Miner Res, 11
- Kaneki, 1991, The effect of menopause on IL-1 and IL-6 release from peripheral blood monocytes, J Bone Miner Res, 6, 76
- Thompson, 1991, IL-lra: Properties and uses of an interleukin-1 receptor antagonist, Agents Actions, 41
- Girasole, 1995, Increased serum soluble interleukin-6 receptor levels are induced by ovariectomy, prevented by estrogen replacement, and reversed by alendronate administration, J Bone Miner Res, 10, A86
- McKane, 1993, Effect of age and menopause on serum interleukin-1β and intereleukin-6- levels in women, J Bone Miner Res, 8, 162A
- Kimble, 1994, Long-term treatment with IL-1 receptor antagonist (IL-lra) blocks bone loss in ovariectomized rats, J Bone Miner Res, 9, B380
- Kimble, 1995, Inhibition of IL-6 activity is genetically normal mice does not prevent ovariectomy-induced bone loss, J Bone Miner Res, 10, s160
- Ammann, 1995, Transgenic mice expressing high levels of soluble tumor necrosis factor receptor-1 fusion protein are protected from bone loss caused by estrogen deficiency, J Bone Miner Res, 10
Cited by
Items 101–200 of 743
Uchiyama, Y., HiguchI, Y., Takeda, S., Masaki, T., Shiraishi, A., Sato, K., Kubodera, N., Ikeda, K., & Ogata, E. (2002) · Bone · doi:10.1016/s8756-3282(02)00682-8 · Cited by 126
Hofbauer, L. C. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410195 · Cited by 138
Bone mass and mineral metabolism in HIV+ postmenopausal women
Yin, M. T., Dobkin, J. F., Brudney, K. F., Becker, C., Zadel, J. L., Manandhar, M., Addesso, V., & Shane, E. J. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1845-0 · Cited by 119
“Estrogen down-regulates many of the proinflammatory cytokines (TNF-a, IL-1, Il-6) that increase bone resorption [2,32].”
BackgroundThe Ovariectomized Rat as a Model for Studying Alveolar Bone Loss in Postmenopausal Women
Johnston, B. D., & Ward, W. E. (2015) · BioMed Research International · doi:10.1155/2015/635023 · Cited by 123
“Specifically, the number of osteoclasts increases to a point where the rate of bone resorption exceeds the rate of bone formation [2].”
BackgroundMechanisms and Regulation of Epithelial Ca2+ Absorption in Health and Disease
Suzuki, Y., Landowski, C. P., & Hediger, M. A. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.031905.161003 · Cited by 115
Antiosteoporotic compounds from seeds of Cuscuta chinensis
Yang, L., Chen, Q., Wang, F., & Zhang, G. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.03.056 · Cited by 118
Hikiji, H., Takato, T., Shimizu, T., & Ishii, S. (2007) · Progress in Lipid Research · doi:10.1016/j.plipres.2007.12.003 · Cited by 123
“In contrast, mouse osteoblasts expressed much lower levels of PAFR mRNA even after stimulation with TNF-a and IL-1b simultaneously.”
BackgroundInfluentialBu, S. Y., Lerner, M. R., Stoecker, B. J., Boldrin, E., Brackett, D. J., Lucas, E. A., & Smith, B. J. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9139-0 · Cited by 126
“Inflammatory mediators such as NO have been recognized in recent years for their role in the pathogenesis of osteoporosis [40].”
BackgroundReduction of dietary magnesium by only 50% in the rat disrupts bone and mineral metabolism
Rude, R. K., Gruber, H. E., Norton, H. J., Wei, L. Y., Frausto, A., & Kilburn, J. M. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0104-3 · Cited by 121
“Increased production of these cytokines has been implicated in the development of sex steroid deficiency or postmenopausal osteoporosis [ 82 , 83].”
BackgroundPandey, A. K., Misra, P., Khan, M. P., Swarnkar, G., Tiwari, M. C., Bhambhani, S., Trivedi, R., Chattopadhyay, N., & Trivedi, P. K. (2013) · Plant Biotechnology Journal · doi:10.1111/pbi.12118 · Cited by 124
Li, J., & Wang, H. (2008) · Implant Dentistry · doi:10.1097/id.0b013e31818c4992 · Cited by 121
Torekov, S. S., Harsløf, T., Rejnmark, L., Eiken, P., Jensen, J. B., Herman, A. P., Hansen, T., Pedersen, O., Holst, J. J., & Langdahl, B. L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3766 · Cited by 109
“After menopause, bone is lost due to the diminished levels of estrogen, a strong inhibitor of osteoclast activity (17).”
BackgroundBlum, C. A., Müller, B., Huber, P., Kraenzlin, M., Schindler, C., De Geyter, C., Keller, U., & Puder, J. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0231 · Cited by 107
“Thus, the effect of estrogen on bone metabolism is thought to be modulated through bone-resorbing cytokines like IL-1, IL-6, and TNF (10, 24, 26).”
BackgroundVidal, O., Sjögren, K., Eriksson, B. I., Ljunggren, Ö., & Ohlsson, C. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9035 · Cited by 114
Berberoglu, Z., Gursoy, A., Bayraktar, N., Yazici, A. C., Bascil Tutuncu, N., & Guvener Demirag, N. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0431 · Cited by 108
c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs
Takasu, H., Sugita, A., Uchiyama, Y., Katagiri, N., Okazaki, M., Ogata, E., & Ikeda, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24742 · Cited by 108
“Osteoclast activation in estrogen deficiency involves diverse mechanisms, including the production of bone-resorbing cytokines in the bone microenvironment (10, 11) in addition to estrogen’s direct effect on osteoclasts and their precursors (12).”
BackgroundWilkinson, J. M., Hamer, A. J., Rogers, A., Stockley, I., & Eastell, R. (2003) · Journal of Orthopaedic Research® · doi:10.1016/s0736-0266(02)00237-1 · Cited by 104
Advanced Glycation Endproducts Stimulate Interleukin-6 Production by Human Bone-Derived Cells
Takagi, M., Kasayama, S., Yamamoto, T., Motomura, T., Hashimoto, K., Yamamoto, H., Sato, B., Okada, S., & Kishimoto, T. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.3.439 · Cited by 105
Barkhem, T., Nilsson, S. V., & Gustafsson, J. K. (2004) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200404010-00003 · Cited by 115
M-CSF neutralization and Egr-1 deficiency prevent ovariectomy-induced bone loss
Cenci, S., Weitzmann, M. N., Gentile, M. A., Aisa, M. C., & Pacifici, R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8672 · Cited by 103
“Among them are IL-1, IL-6, TNF, M-CSF, and osteoprotegerin (1, 11, 16, 17, 19).”
Self-citationAris, R. M., STEPHENS, A. R., Ontjes, D. A., Blackwood, A. D., Lark, R. K., HENSLER, M. B., Neuringer, I. P., & Lester, G. E. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.5.2002100 · Cited by 101
Regulation of osteoclast activity
Greenfield, E. M., Bi, Y., & Miyauchi, A. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00156-3 · Cited by 121
Bu, S. Y., Hunt, T. S., & Smith, B. J. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2007.11.012 · Cited by 107
“Under conditions of gonadal hormone deficiency, decreased osteoblast activity and promotion of osteoclast differentiation by inflammatory cytokines such as TNF-α are associated with a defective antioxidant system [14].”
BackgroundFaroqui, S., Levi, M., Soleimani, M., & Amlal, H. (2008) · Kidney International · doi:10.1038/ki.2008.33 · Cited by 99
Higher Rates of Bone Loss in Postmenopausal HIV-Infected Women: A Longitudinal Study
Yin, M. T., Zhang, C. A., McMahon, D. J., Ferris, D. C., Irani, D., Colón, I., Cremers, S., & Shane, E. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2197 · Cited by 98
“Because estrogen mitigates the proresorptive effects of inflammatory cytokines, which are up-regulated in HIV infection, on bone remodeling, we hypothesized that bone loss may accelerate in HIV women during the menopausal transition (29).”
BackgroundPavalko, F. M., Gerard-O’Riley, R. L., Ponik, S. M., Gallagher, P. J., Jin, Y., & Norvell, S. M. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10221 · Cited by 98
“TNF-aplays an important role in bone diseases including postmenopausal osteoporosis and rheumatoid arthritis (Pacifici, 1996; Boyce et al., 1999).”
BackgroundMethodMadeddu, G., Spanu, A., Chessa, F., Calia, G. M., Lovigu, C., Solinas, P., Mannazzu, M., Falchi, A., Mura, M. S., & Madeddu, G. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02472.x · Cited by 97
Sato, T., Shibata, T., Ikeda, K., & Watanabe, K. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.12.2215 · Cited by 99
“(1–3) Estrogen deficiency is known to in crease the local production of proinflammatory cytokines such as TNFa,((6)) IL-1,((5,6)) and IL-6,((5)) which induce RANKL expression either directly (11) or indirectly via prostaglandin E2, (12) thereby stimulating osteoclastogenesis.”
BackgroundHu, X., Wang, Z., Wang, W., Cui, P., Kong, C., Chen, X., & Lu, S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.09.001 · Cited by 99
The Anti-Inflammatory Role of Vitamin E in Prevention of Osteoporosis
Shuid, A. N., Norazlina, M., Norliza, M., & Nirwana, S. I. (2011) · Advances in Pharmacological Sciences · doi:10.1155/2012/142702 · Cited by 102
“Macrophage colony stimulating factor (MCSF) is another important determinant of osteoclastogenesis, but its mechanism to modulate osteoclastogenesis is still not clear [20].”
BackgroundVural, P., Akgül, C., & Canbaz, M. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.06.006 · Cited by 105
Matayoshi, A., Brown, C., DiPersio, J. F., Haug, J., Abu‐Amer, Y., Liapis, H., Kuestner, R. E., & Pacifici, R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10785 · Cited by 98
Self-citationAttenuation of osteoclastogenesis and osteoclast function by apigenin
Bandyopadhyay, S., Lion, J.-M., Mentaverri, R., Ricupero, D. A., Kamel, S., Romero, J. R., & Chattopadhyay, N. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.04.018 · Cited by 100
“[18] Pacifici R.”
BackgroundXiao, P., Chen, Y., Jiang, H., Liu, Y.-Z., Pan, F., Yang, T., Tang, Z.-H., Larsen, J. A., Lappe, J. M., Recker, R. R., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080105 · Cited by 98
“The significance of the association between the data set and the canonical pathway was measured in two ways: (1) a ratio of the number of genes from the data set that map to the pathway divided by the total number of genes that map to the canonical pathway is displayed; and (2) a Fisher’s exact test was used to calcul…”
MethodBhat-Nakshatri, P., Newton, T. R., Goulet, R., & Nakshatri, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6971 · Cited by 90
Studies on the Potential Mediators of Skeletal Changes Occurring during Puberty in Girls
Libanati, C. R., Baylink, D. J., Lois-Wenzel, E., Srinivasan, N., & Mohan, S. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5905 · Cited by 98
“These changes, which are just mirror images of those occurring during the menopause, support the role of IL-6 in mediating rapid changes in bone density (39, 42).”
Remodeling of junctional complexes during the development of the outer blood-retinal barrier
Williams, C. D., & Rizzolo, L. J. (1997) · The Anatomical Record · doi:10.1002/(sici)1097-0185(199711)249:3<380::aid-ar9>3.0.co;2-y · Cited by 61
How menopause affects oral health, and what we can do about it
Buencamino, M. C. A., Palomo, L., & Thacker, H. L. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76a.08095 · Cited by 103
Expression of Extracellular Calcium (Ca2+o)-Sensing Receptor in Human Peripheral Blood Monocytes
Yamaguchi, T., Olozak, I., Chattopadhyay, N., Butters, R. R., Kifor, O., Scadden, D. T., & Brown, E. M. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8648 · Cited by 89
Abrahamsen, B., Bonnevie-Nielsen, V., Ebbesen, E. N., Gram, J., & Beck-Nielsen, H. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1545 · Cited by 90
“These include “upstream” cytokines (interleukin-1b [IL-1b], tumor necrosis factora [TNF-a], IL-6, and IL-11)((5,6)) as well as “downstream” cytokines, such as osteoprotegerin ligand (OPG-L; also known as TNF-related activation–induced cytokine [TRANCE] *Presented in part as an abstract at the Annual Meeting of the Ame…”
BackgroundInhibition of p38 Mitogen-Activated Protein Kinase Prevents Inflammatory Bone Destruction
Mbalaviele, G., Anderson, G. D., Jones, A., Ciechi, P. D., Settle, S., Mnich, S., Thiede, M. A., Abu‐Amer, Y., Portanova, J. P., & Monahan, J. B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100362 · Cited by 97
“This includes TNF- , IL-1 , and other factors (Pacifici, 1996).”
BackgroundA bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss
Goswami, J., Hernández‐Santos, N., Zuniga, L. A., & Gaffen, S. L. (2009) · European Journal of Immunology · doi:10.1002/eji.200939670 · Cited by 87
“Estrogen deficiency also increases the RANKL:OPG ratio through increases in pro-inflammatory effectors, including IL-1b, IL-6, IL-11, TNF-a, M-CSF and PGE2 [33–35].”
A PCR Analysis of ERα and ERβ mRNA Abundance in Rats and the Effect of Ovariectomy
Lim, S., Won, Y. J., Lee, H. C., Huh, K. B., & Park, Y. S. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.7.1189 · Cited by 96
“Osteoclast formation was decreased by the inhibition of IL-6, and estrogen withdrawal stimulated the proliferation of hematopoietic osteoclast precursors originating from cells of the granulocyte macrophage colony stimulating unit or macrophage colony stimulating unit lineage.((22)) Therefore, the effects of estrogen…”
BackgroundSui, B., Chen, J., Zhang, X., He, T., Zhao, P., Zheng, C., Li, M., Hu, C., & Jin, Y. J. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0192-0 · Cited by 89
Nutrition, Osteoporosis, and Aging
NORDIN, B. E. C., NEED, A. G., STEURER, T., MORRIS, H. A., CHATTERTON, B. E., & HOROWITZ, M. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09914.x · Cited by 84
“This raises the possibility that estrogen deficiency exerts its effect on bone indirectly by increasing calcium requirement rather than by a direct action on bone cells, although there is evidence of the latter from in vitro studies.(14)”
Bone and Cytokines: Beyond IL-1, IL-6 and TNF-α
Rifas, A. (1999) · Calcified Tissue International · doi:10.1007/s002239900570 · Cited by 98
“And recently, bone loss has been prevented in OVX rats treated with the IL-1 and TNF-a inhibitors, IL-1 receptor antagonist and TNF binding protein, respectively, suggesting that IL-1 and TNF-a regulate postmenopausal bone resorption [37].”
BackgroundPostmenopausal changes in serum cytokine levels and hormone replacement therapy
Kamada, M., Irahara, M., Maegawa, M., Ohmoto, Y., Takeji, T., Yasui, T., & Aono, T. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.109940 · Cited by 84
Heer, M., Mika, C., Grzella, I., Drummer, C., & Herpertz-Dahlmann, B. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.5.754 · Cited by 84
“Starvation is accompanied by high serum cortisol, which enhances bone resorption (10 ). Estrogen is an important hormone for bone mineralization ( 22 ). Although in postmenopausal women the administration of oral estrogen has been shown to be successful in counteracting decreases in BMD (23 ), it seems ineffective in…”
BackgroundEndogenous n-3 fatty acids protect ovariectomy induced bone loss by attenuating osteoclastogenesis
Rahman, M. M., Bhattacharya, A., Banu, J., Kang, J. X., & Fernandes, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00649.x · Cited by 88
Protective role of n-3 lipids and soy protein in osteoporosis
Fernandes, G., Lawrence, R. A., & Sun, D. (2003) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(03)00060-7 · Cited by 94
“Since IL-1a, IL-6, and TNF-a are closely linked to the activation of osteoclasts [73–76] and PGE2 has also been found to accelerate bone loss [77,78], we have begun studies related to osteoporosis in OVX mice fed n-6 and n-3 lipids with casein and soy protein diets.”
BackgroundKenny, A. M., & Prestwood, K. M. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70157-5 · Cited by 97
Gaudio, A., Morabito, N., Catalano, A., Rapisarda, R., Xourafa, A., & Lasco, A. (2019) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2018.2018.0074 · Cited by 82
“Cytokines other than RANKL and OPG, such as interleukin (IL)-1α, IL-6 and tumor necrosis factor-α, that are largely recognised as important effectors in the pathogenesis of several forms of osteoporosis (44,45,46,47), could have a role in TM-related osteoporosis.”
BackgroundAscott-Evans, B. H., Guañabens, N., Kivinen, S., Stuckey, B. G. A., Magaril, C., Vandormael, K., Stych, B., & Melton, M. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.7.789 · Cited by 87
“Estrogen withdrawal, whether due to menopause or to discontinuation of HRT, has been shown to be associated with an increase in the release of bone-resorbing cytokines such as interleukin 1 and tumor necrosis factor.(22,23) Therefore, increased bone resorption is thought to be the mechanism responsible for the acceler…”
BackgroundThe mutual dependence between bone and gonads
Karsenty, G. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0452 · Cited by 90
“…favor osteoclast apoptosis by decreasing the production of cytokines, such as interleukin 1 (IL1), IL6, tumor necrosis factor a (TNFa), and macrophage colonystimulating factor (Hughes et al. 1996, Jimi et al. 1996, Pacifici 1996, Manolagas et al. 2002, Riggs et al. 2002, Xing & Boyce 2005).”
BackgroundMcKay, T. B., Hjortdal, J., Sejersen, H., Asara, J. M., Wu, J., & Karamichos, D. (2016) · Scientific Reports · doi:10.1038/srep25534 · Cited by 86
Soliman, A. T., El-Banna, N., Fattah, M. A., ElZalabani, M. M., & Ansari, B. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90237-2 · Cited by 84
Herrington, D. M. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4216 · Cited by 80
“Numerous in vitro studies have demonstrated that E suppresses IL-1, IL-1 receptor, IL-6, and TNF expression in tissue cultures of human or murine osteoblasts (6, 35, 36), marrow stromal cells (35, 37, 38), circulating monocytes (7), human umbilical vein endothelial cells (8), splenic macrophages (39), and even atheros…”
Effect of Estrogen Deficiency on Skeletal and Alveolar Bone Density in Sheep
Johnson, R. B., Gilbert, J. A., Cooper, R. C., Parsell, D. E., Stewart, B. A., Dai, X., Nick, T. G., Streckfus, C. F., Butler, R., & Boring, J. G. (2002) · Journal of Periodontology · doi:10.1902/jop.2002.73.4.383 · Cited by 78
GOLUB, L. M., RAMAMURTHY, N. S., LLAVANERAS, A., RYAN, M. E., LEE, H. M., LIU, Y., BAIN, S., & SORSA, T. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07691.x · Cited by 81
Berglundh, S., Malmgren, L., Luthman, H., McGuigan, F. E., & Åkesson, K. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2951-7 · Cited by 80
“the bone loss associated with aging and estrogen depletion [14].”
BackgroundCentral IL-1 receptor signaling regulates bone growth and mass
Bajayo, A., Goshen, I., Feldman, S., Csernus, V., Iverfeldt, K., Shohami, E., Yirmiya, R., & Bab, I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502562102 · Cited by 78
Janele, D., Lang, T., Capellino, S., Cutolo, M., da Silva, J. A. P., & Straub, R. H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1351.015 · Cited by 77
Yun, A. J., & Lee, P. Y. (2004) · Medical Hypotheses · doi:10.1016/s0306-9877(03)00326-8 · Cited by 76
“IL-1, IL-6, TNF-a, GM-CSF, MCSF, and PGE2 have been shown to increase bone resorption through indirect or direct modulation of osteoclasts [3–6].”
BackgroundThe Endocannabinoid/Endovanilloid System in Bone: From Osteoporosis to Osteosarcoma
Rossi, F., Tortora, C., Punzo, F., Bellini, G., Argenziano, M., Paola, A. D., Torella, M., & Perrotta, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081919 · Cited by 78
“In post-menopause, estrogen withdrawal seems to delay osteoclast apoptosis inducing a lower bone mass density [47,51,52].”
Hofbauer, L. C., Ten, R. M., & Khosla, S. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.8.1330 · Cited by 77
“While the effects of estrogen on bone are better studied, and it is clear that, in addition to direct effects on both osteoblasts and osteoclasts, estrogen may regulate the production of various cytokines that act as paracrine and autocrine mediators,((2,4,5)) the cellular and molecular mechanisms of androgen action o…”
Backgroundα-Lipoic Acid Inhibits TNF-α-Induced Apoptosis in Human Bone Marrow Stromal Cells
Byun, C.-H., Koh, J., Kim, D. K., Park, S.-I., Lee, K., & Kim, G. S. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050302 · Cited by 85
“important role mediating bone loss induced by estrogen deficiency,((12,13)) these data support the antagonistic effects”
BackgroundEssential fatty acids and osteoporosis
Das, U. N. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00262-8 · Cited by 74
Oh, K. W., Rhee, E. J., Lee, W. Y., Kim, S. W., Baek, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Ihm, S. H., Choi, M. G., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02179.x · Cited by 73
Blaschke, M., Koepp, R., Cortis, J., Komrakova, M., Schieker, M., Hempel, U., & Siggelkow, H. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/67561 · Cited by 73
Biological agents in management of osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1735-5 · Cited by 78
Life-Long Caloric Restriction Reveals Biphasic and Dimorphic Effects on Bone Metabolism in Rodents
Tatsumi, S., Ito, M., Asaba, Y., Tsutsumi, K., & Ikeda, K. (2008) · Endocrinology · doi:10.1210/en.2007-1089 · Cited by 67
The effect of sex hormones on bone metabolism of the otic capsule – an overview
Horner, K. C. (2008) · Hearing Research · doi:10.1016/j.heares.2008.12.004 · Cited by 85
Walsh, B. W., Cox, D. A., Sashegyi, A. I., Dean, R. A., Tracy, R. P., & Anderson, P. W. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01865-3 · Cited by 75
Ham, K. D., & Carlson, C. S. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040309 · Cited by 69
The Effect of In Vivo Mechanical Loading on Estrogen Receptor α Expression in Rat Ulnar Osteocytes
Ehrlich, P. J., Noble, B. S., Jessop, H. L., Stevens, H. Y., Mosley, J. R., & Lanyon, L. E. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.9.1646 · Cited by 70
Peripheral Blood Monocyte-expressed ANXA2 Gene is Involved in Pathogenesis of Osteoporosis in Humans
Deng, F., Lei, S., Zhang, Y., Zhang, Y.-L., Zheng, Y.-P., Zhang, L.-S., Pan, R., Wang, L., Tian, Q., Shen, H., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.011700 · Cited by 72
Kassem, A., Lindholm, C., & Lerner, U. H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156708 · Cited by 71
“Osteoblasts are resident cells that communicate and activate osteoclastogenesis in bone tissue by producing RANKL in response to a variety of bone resorbing hormones and cytokines [48,49].”
BackgroundThe Effect of Anti‐TNF‐α Therapy on Spinal Bone Mineral Density in Patients with Crohn's Disease
PAZIANAS, M., RHIM, A. D., WEINBERG, A. M., SU, C., & LICHTENSTEIN, G. R. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.055 · Cited by 69
Impact of the Ovulatory Cycle on Virologic and Immunologic Markers in HIV‐Infected Women
Greenblatt, R. M., Ameli, N., Grant, R. M., Bacchetti, P., & Taylor, R. N. (2000) · The Journal of Infectious Diseases · doi:10.1086/315207 · Cited by 73
High prevalence of increased interleukin-17A serum levels in postmenopausal estrogen deficiency
Molnár, I., Bohaty, I., & Somogyiné-Vári, É. (2014) · Menopause · doi:10.1097/gme.0000000000000125 · Cited by 66
“Estrogen deficiency modulates the renin-angiotensin system and increases the production of interleukin (IL)-1, IL-6, tumor necrosis factor->, and granulocyte-macrophage colony-stimulating factor.(2,3) Estrogen is involved in T helper 17 (TH17) cell differentiation, inhibiting IL-17 (also known as IL-17A) production.”
BackgroundRegulation of Sealing Ring Formation by L-plastin and Cortactin in Osteoclasts
Ma, T., Sadashivaiah, K., & Chellaiah, M. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.099697 · Cited by 74
Harrod, C. G., Batjer, H. H., & Bendok, B. R. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.09.051 · Cited by 73
“These findings are consistent with the observed increases in interleukin-1 (IL-1) and TNF in postmenopausal women concomitant with the risk of osteoporosis and heart disease, and the amelioration of these diseases upon initiation of ERT [74].”
ResultCloning and Function of Rabbit Peroxisome Proliferator-activated Receptor δ/β in Mature Osteoclasts
Mano, H., Kimura, C., Fujisawa, Y., Kameda, T., Mikiko, W.-M., Kaneko, H., Kaneda, T., Hakeda, Y., & Kumegawa, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8126 · Cited by 74
Graham, S. M., Hammond-Jones, D., Gamie, Z., Polyzois, I., Tsiridis, E., & Tsiridis, E. E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.9.1281 · Cited by 71
“They have an effect on bone by restraining the production of cytokines interleukin-1 and interleukin-6 (IL-1, IL-6) and tumour necrosis factor α (TNFα ) in the bone marrow and therefore reduction in oestrogen stimulates osteoclastogenesis [11,17] .”
BackgroundA crosstalk between bone and gonads
Oury, F. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06360.x · Cited by 71
ADRENAL AND GONADAL STEROIDS INHIBIT IL-6 SECRETION BY HUMAN MARROW CELLS
Gordon, C. M., LeBoff, M. S., & Glowacki, J. (2001) · Cytokine · doi:10.1006/cyto.2001.0962 · Cited by 67
The “lively” cytokines network in β-Thalassemia Major-related osteoporosis
Morabito, N., Russo, G. T., Gaudio, A., Lasco, A., Catalano, A., Morini, E., Franchina, F., Maisano, D., Rosa, M. L., Plota, M., et al. (2007) · Bone · doi:10.1016/j.bone.2007.02.020 · Cited by 71
“Cytokines are largely recognized as important effectors in the pathogenesis of several forms of osteoporosis [25–37]; however, there are no data on their impact in βTM-osteoporosis.”
BackgroundHuang, W., Shang, W.-L., Wang, H., Wu, W., & Hou, S. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.189 · Cited by 67
Bonnelye, E., Kung, V., Laplace, C., Galson, D. L., & Aubin, J. E. (2002) · Endocrinology · doi:10.1210/en.2002-220095 · Cited by 72
Critical Role of β3 Integrin in Experimental Postmenopausal Osteoporosis
Zhao, H., Kitaura, H., Sands, M. S., Ross, F. P., Teitelbaum, S. L., & Novack, D. V. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050724 · Cited by 64
“which stimulates osteoclast precursors to differentiate and prompts the mature cell to resorb bone.((21,22)) Because v 3”
BackgroundType I Collagen Structure, Synthesis, and Regulation
Bou–Gharios, G., & Crombrugghe, B. D. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00034-3 · Cited by 75
Yoneda, T., Ishimaru, N., Arakaki, R., Kobayashi, M., Izawa, T., Moriyama, K., & Hayashi, Y. (2004) · Endocrinology · doi:10.1210/en.2003-1536 · Cited by 60
Damani, J. J., Souza, M. J. D., VanEvery, H., Strock, N. C. A., & Rogers, C. J. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab162 · Cited by 66
Physical training increases osteoprotegerin in postmenopausal women
Bergström, I. B., Parini, P., Gustafsson, S. A., Andersson, G., & Brinck, J. W. (2011) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-011-0304-6 · Cited by 63
“In vitro experiments using human osteoblast cell lines have demonstrated an up-regulation of OPG in response to estradiol [8], and treatment of healthy humans with an inactivating monoclonal antibody against RANKL led to reduced levels of serum markers of bone resorption and formation [9].”
BackgroundRANK ligand and the regulation of skeletal remodeling
Bell, N. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18358 · Cited by 77
Interaction Between Nitric Oxide Synthase and Cyclooxygenase Pathways in Osteoblastic MC3T3-E1 Cells
Kanematsu, M., Ikeda, K., & Yamada, Y. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.11.1789 · Cited by 60
“IL-1((27)) and TNF-a((28)) stimulate bone resorption and inhibit bone formation, and accumulating evidence suggests that these proinflammatory cytokines are involved in the pathogenesis of osteoporosis.((29,30)) However, the cellular and molecular mechanisms by which these cytokines act in the bone microenvironment re…”
BackgroundRossi, F., Bellini, G., Torella, M., Tortora, C., Manzo, I., Giordano, C. S. D. S., Guida, F., Luongo, L., Papale, F., Rosso, F., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12542 · Cited by 61
“Postmenopausal OP, the most frequent type of primary OP, is considered to be consequence of several factors, such as the lifestyle, dietary habits and, most importantly, the age-related decrease in sex steroidal hormones (Pacifici, 1996; Corina et al., 2012).”
BackgroundFurther evidence for direct pro-resorptive actions of FSH
Sun, L., Zhang, Z., Zhu, L., Peng, Y., Liu, X., Li, J., Agrawal, M., Robinson, L. J., Iqbal, J. Z., Blair, H. C., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.113 · Cited by 62
Bioactivity‐guided Isolation of Antiosteoporotic Compounds from Ligustrum lucidum
Chen, Q., Yang, L., Zhang, G., & Wang, F. (2012) · Phytotherapy Research · doi:10.1002/ptr.4820 · Cited by 60
“Due to the important roles of estrogen in maintaining the balance between osteoblasts and osteoclasts in bone homeostasis, estrogen replacement therapy has become the established regimen for prevention of postmenopausal bone loss (Pacifici, 1996).”
BackgroundInfluentialNon‐genomic inhibition of human P2X 7 purinoceptor by 17β‐oestradiol
Cario‐Toumaniantz, C., Loirand, G., Ferrier, L., & Pacaud, P. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.659bp.x · Cited by 62
“Hormone replacement therapy of postmenopausal women using oestrogen significantly reduces the risk of cardiovascular disease and osteoporosis (Pacifici, 1996; Nathan & Chaudhuri, 1997).”
Background
Metadata
- Authors
- Pacifici, R.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Pacifici, Roberto
- ORCID
- Pacifici, Roberto
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-08-01
- Volume
- 11
- Issue
- 8
- Pages
- 1043-1051
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2110993073
- Cited by
- 741
- References
- 90
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 15 · 2023: 20 · 2022: 20 · 2021: 24 · 2020: 20 · 2019: 26 · 2018: 30 · 2017: 15 · 2016: 19 · 2015: 31 · 2014: 29 · 2013: 22 · 2012: 28
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag013534-04)
- National Institute on Aging (AG 13534)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR041412, AR41412)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- postmenopausal osteoporosis, estrogen deficiency, cytokines, interleukin-1, TNF-α, bone resorption, osteoclastogenesis, osteoclast apoptosis, bone marrow, cytokine synergy, estrogen withdrawal, cytokine inhibitors
- MeSH terms
- Animals, Bone and Bones, Bone Resorption, Estrogens, Female, Humans, Menopause, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.